A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer

Journal of Thoracic Oncology

Volumn 5, Issue 2, 2010, Pages 229-235

  Rodriguez, Cristina P ^a   Adelstein, David J ^a   Rice, Thomas W ^b   Rybicki, Lisa A ^a   Videtic, Gregory M M ^a   Saxton, Jerrold P ^a   Murthy, Sudish C ^b   Mason, David P ^b   Ives, Denise I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

EGFR inhibition; Esophageal cancer; Gastroesophageal cancer; Multimodality therapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG TOLERABILITY; ECHOGRAPHY; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL JUNCTION CANCER; HISTORICAL RESEARCH; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; UNPLANNED HOSPITALIZATION;

EID: 77649085714     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c5e334     Document Type: Article

References (36)

1. Rice TW, Blackstone EH, Adelstein DJ, et al. N1 esophageal carcinoma: the importance of staging and downstaging. J Thorac Cardiovasc Surg 2001;121:454-464.
2. Rice TW, Adelstein DJ. Precise clinical staging allows treatment modification of patients with esophageal carcinoma. Oncology (Williston Park) 1997;11:58-62.
3. Burmeister BH, Smithers BM, Gebski V, et al; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659-668.
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
5. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
6. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-1092.
7. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
8. Gebski V, Burmeister B, Smithers BM, et al; Australasian Gastro- Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-234.
9. Adelstein DJ, Rice TW, Rybicki LA, et al. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity. Am J Clin Oncol 2007;30:172-180.
10. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74:795-804.
11. Iihara K, Shiozaki H, Tahara H, et al. Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 1993;71:2902-2909.
12. Wang KL, Wu TT, Choi IS, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007;109:658-667.
13. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-4927.
14. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13: 5869-5875.
15. Adelstein DJ, Rybicki LA, Carroll MA, et al. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. J Clin Oncol ASCO Annual Meeting Proceedings 2005; 23(Suppl 16):(abstract).
16. Greene FL. American Joint Committee on Cancer: AJCC Cancer Staging Manual, 6th Ed. New York: Springer-Verlag, 2002.
17. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;25:4880-4886.
18. Hainsworth JD, Spigel DR, Burris HA III, et al. Neoadjuvant chemotherapy/ gefitinib followed by concurrent chemotherapy/radiation therapy/ gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009;115:2138-2146.
19. Malaisrie SC, Hofstetter WL, Correa AM, et al. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 2006;107:967-974.
20. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
21. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
22. Herbst RS, Prager D, Hermann R, et al; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall- cell lung cancer. J Clin Oncol 2005;23:5892-5899.
23. Gregorc V, Hidalgo M, Spreafico A, et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 2008;83:477-484.
24. Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006;98:1739-1742.
25. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
26. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
27. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet 2009;373:1525-1531.
28. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
29. Heeren PA, Jager PL, Bongaerts F, et al. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 2004;45:980-987.
30. Meyers BF, Downey RJ, Decker PA, et al; American College of Surgeons Oncology Group Z0060. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007;133:738-745.
31. Kato H, Miyazaki T, Nakajima M, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005;103:148-156.
32. Adelstein DJ, Rice TW, Becker M, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 1997;80:1011-1020.
33. Forastiere AA, Heitmiller RF, Lee DJ, et al. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am 1997;3:144-152.
34. Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000;18:868-876.
35. Urba SG, Orringer MB, Ianettonni M, et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003;98:2177-2183.
36. Kelsen DP, Winter KA, Gunderson LL, et al; Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719-3725.